EN DE
Watch LegoChem Biosciences Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

LegoChem Biosciences Inc (141080) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of LegoChem Biosciences Inc stock KRW 37,490, price KRW 55,400, that is 32.3% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7141080002

LB LegoChem Biosciences Inc logo Thin data Nov 17, 2026

LegoChem Biosciences Inc

141080 · KQ

Expensive (fair value 32% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Expensive Growth (revenue 5y +23.4 %/yr in KRW) 
Revenue last quarter 83% below a year ago. 
Fair value 37,490 KRW · Overvalued 
Quality 38/100 
Falling price (downtrend) 
Loss-making · -180.9% net margin (TTM) 
Negative free cash flow 
Trails peers (2/9) 
Narrow moat 12/100 · thin data
Thin data 
Estimate
Watch LegoChem Biosciences Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

213,500 KRW 30,650 KRW Fair Value 37,490 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range 30,650 KRW – 213,500 KRW · fair‑value band 28,118 KRW – 46,863 KRW · the 55,400 KRW price screens above the 37,490 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow LegoChem Biosciences in your weekly email

Every Wednesday you see whether LegoChem Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs.

Show moreShow less

The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies.

It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was formerly known as LegoChem Biosciences, Inc. and changed its name to LigaChem Biosciences Inc. in April 2024.

LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

Stock analysis

LegoChem Biosciences Inc (141080) currently trades at 55,400 KRW, while our estimate is 37,490 KRW, 32% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 28,118 KRW (bear) to 46,863 KRW (bull), the price of 55,400 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

LegoChem Biosciences Inc reported revenue of 142B KRW in FY2025 versus 32.2B KRW in FY2021, a compound +44.8%/yr. Reported net income was −74.3B KRW in FY2025.

Key figures

Market cap 2.5T KRW (≈ $1.8B) Small · P/S ratio 24.9 · EPS (TTM) −4,517 KRW · Net margin −52.5% · Return on equity −36.6% · Return on assets (EBIT) −18.0% (5-year average) · Operating margin −208% · Revenue (TTM) 98.8B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 74% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −32%, 141080 screens richer than that median.

Fair Value

Bear 28,118 KRW Fair Value 37,490 KRW Bull 46,863 KRW
Price 55,400 KRW · Downside -32.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 38
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 86
Debt, balance sheet and risk of trouble
Investment 29
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.4%
Start year 2020 (pandemic). Over 10 years: +54.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−59.7% (2020) → −75.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

141080 screens overvalued: fair value 32% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare LegoChem Biosciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −32.3% · Below median
Profitability
Return on assets −10.6% · Above median
Net margin (12 months) −180.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −83.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.85× · Pricier than median
P/S (12 months) 24.91× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 141080
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 141080
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 141080
argenx SE ARGX $950.95 $908.40 −4% vs 141080
CSL Limited CSL A$199.55 A$186.49 −7% vs 141080
Moderna, Inc MRNA $215.27 $135.64 −37% vs 141080
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 141080
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 141080
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 141080
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 141080

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LegoChem Biosciences Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "LegoChem Biosciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/141080

Frequently asked questions

Is LegoChem Biosciences Inc (141080) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is 37,490 KRW versus a price of 55,400 KRW, about 32% lower (overvalued).
What is the fair value of 141080?
Our estimate for LegoChem Biosciences Inc is 37,490 KRW (as of Nov 17, 2026), built from audited fundamentals. The current price: 55,400 KRW.
What is the quality score of 141080?
LegoChem Biosciences Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LegoChem Biosciences Inc (141080)?
Our calculated price target is the estimate of 37,490 KRW (as of Nov 17, 2026). Cautious scenario 28,118 KRW, optimistic scenario 46,863 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the LegoChem Biosciences Inc stock forecast for 2026?
Our estimate puts fair value at 37,490 KRW, about 32% lower versus a price of 55,400 KRW (overvalued). Cautious scenario 28,118 KRW, optimistic scenario 46,863 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of LegoChem Biosciences Inc (141080)?
LegoChem Biosciences Inc reported trailing-twelve-month revenue of about 98.8B KRW (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of LegoChem Biosciences Inc (141080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LegoChem Biosciences Inc it is 37,490 KRW per share (as of Nov 17, 2026), against a price of 55,400 KRW.
Is LegoChem Biosciences Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, 141080 trades above its calculated fair value: price 55,400 KRW, fair value 37,490 KRW, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 141080?
No. The price is what the market pays today (55,400 KRW); the fair value is what the company's own numbers justify (37,490 KRW). For LegoChem Biosciences Inc the two are 17,910 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is LegoChem Biosciences Inc worth?
The market values LegoChem Biosciences Inc at about 2.5T KRW (market capitalisation, as of Nov 17, 2026). Per share that is 55,400 KRW; our models calculate a fair value of 37,490 KRW per share.
What do the bullish and bearish scenarios say about 141080?
Our models span a range for LegoChem Biosciences Inc: cautious scenario 28,118 KRW, base 37,490 KRW, optimistic 46,863 KRW per share (as of Nov 17, 2026, price 55,400 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LegoChem Biosciences Inc (141080)?
Balance-sheet figures for LegoChem Biosciences Inc (as of Nov 17, 2026): return on equity −36.6%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 141080 from its 52-week high?
LegoChem Biosciences Inc trades at 55,400 KRW, about 74% below its 52-week high of 213,500 KRW and at the low of 55,400 KRW (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 37,490 KRW is for.
Which stocks are comparable to LegoChem Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LegoChem Biosciences Inc stock attractive at the current price?
The data as of Nov 17, 2026: price 55,400 KRW, calculated fair value 37,490 KRW (−32%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. LegoChem Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LegoChem Biosciences Inc (141080)?
The closing price on Nov 16, 2026 was 55,400 KRW. Our estimate is 37,490 KRW, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LegoChem Biosciences Inc right now?
The price sits above even our optimistic bull case (46,863 KRW). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of LegoChem Biosciences Inc

How large is the market capitalisation of LegoChem Biosciences Inc (141080)?
The market capitalisation of LegoChem Biosciences Inc is 2.5T KRW (≈ $1.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LegoChem Biosciences Inc (141080)?
The price-to-sales ratio of LegoChem Biosciences Inc is 24.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LegoChem Biosciences Inc (141080)?
Earnings per share at LegoChem Biosciences Inc are −4,517 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of LegoChem Biosciences Inc (141080)?
The net margin of LegoChem Biosciences Inc is −52.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LegoChem Biosciences Inc (141080)?
The return on equity (ROE) of LegoChem Biosciences Inc is −36.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LegoChem Biosciences Inc (141080)?
On an EBIT basis the return on assets of LegoChem Biosciences Inc is −18.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LegoChem Biosciences Inc (141080)?
The operating margin of LegoChem Biosciences Inc is −208% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LegoChem Biosciences Inc (141080)?
Revenue at LegoChem Biosciences Inc is down 83.0% versus a year earlier (3y avg +61.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LegoChem Biosciences Inc (141080)?
Earnings per share at LegoChem Biosciences Inc are growing 118% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does LegoChem Biosciences Inc (141080) generate?
The free cash flow of LegoChem Biosciences Inc is −131B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch LegoChem Biosciences Inc in the live analysis

One click puts LegoChem Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.